|Other Names||B-cell CLL/lymphoma 9-like protein, B-cell lymphoma 9-like protein, BCL9-like protein, Protein BCL9-2, BCL9L, DLNB11|
|Target/Specificity||The synthetic peptide sequence is selected from aa 162-176 of HUMAN BCL9L|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).|
|Tissue Location||Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).
Miller, T.C., et al. J. Mol. Biol. 401(5):969-984(2010)
Fritzmann, J., et al. Gastroenterology 137(1):165-175(2009)
Olsen, J.V., et al. Cell 127(3):635-648(2006)
Sampietro, J., et al. Mol. Cell 24(2):293-300(2006)
Brembeck, F.H., et al. Genes Dev. 18(18):2225-2230(2004)
If you have any additional inquiries please email technical services at email@example.com.